Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

After his death, Eli Whitney was described as "one of the most distinguished men who our country as produced." ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Live Updates Deep Dive into ABBV's Earnings Call 11:53 am Looking through AbbVie’s earnings call, these growth prospects stood out: 1. Skyrizi & Rinvoq Set to Dominate Immunology Market 2025 revenue ...

Sun Pharma’s speciality products are in Dermatology, Ophthalmology and Onco-derma therapies including the anchor product Ilumya (for plaque psoriasis ... post 2031 when patents are likely ...

The PREPARE Challenge, sponsored by the NIA, encourages novel approaches for early AD detection using AI-driven tools that improve accuracy, affordability, and accessibility for patients. As a ...

The Alzheimer’s Association advised against diagnosing the disease on biomarkers alone, but other experts said the genie ...

Today, quip, the pioneering design-led oral wellness company, is proud to announce the launch of its groundbreaking innovation: the quip Ultra Next Generation Smart Sonic Toothbrush. Designed in ...

The therapy, designed for moderate to severe plaque psoriasis, marks the company’s third non ... Updates from clinical trials ...